FDA approval for capivasertib: and our new collaboration opportunities for industry partners 17 Nov 2023 The US Food and Drug Administration (FDA) has approved the AKT inhibiting drug capivasertib, now given the brand name Truqap, as a breast cancer treatment. Henry French introduces other current opportunities for industry partners to work with ICR researchers, including in the discovery and development of cancer drugs, and asks – could any become the next capivasertib? Find out more Show/Hide
Commercial partnering opportunities in oncology: a new biomarker test to guide treatment for oestrogen-receptor positive breast cancer 09 Feb 2023 In the first of a series on exciting opportunities for industry to collaborate with scientists at The Institute of Cancer Research, Andrew Czyzewski looks at a new biomarker test developed by Dr Maggie Cheang and colleagues that could guide breast cancer treatment. Find out more Show/Hide